A5089707180- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Platelet Disorders and Treatments
- Acute Myeloid Leukemia Research
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Pleural and Pulmonary Diseases
- Ubiquitin and proteasome pathways
- Eosinophilic Disorders and Syndromes
- Vascular Malformations Diagnosis and Treatment
- Genomic variations and chromosomal abnormalities
- Neonatal Health and Biochemistry
- Lung Cancer Diagnosis and Treatment
- Venous Thromboembolism Diagnosis and Management
- Blood disorders and treatments
- Lung Cancer Research Studies
- NF-κB Signaling Pathways
- Childhood Cancer Survivors' Quality of Life
- Hemophilia Treatment and Research
- Cardiac, Anesthesia and Surgical Outcomes
- Neonatal Respiratory Health Research
- Blood properties and coagulation
- Immunodeficiency and Autoimmune Disorders
- Eosinophilic Esophagitis
- Glioma Diagnosis and Treatment
Saitama Children's Medical Center
2018-2024
Maryland Oncology Hematology
2022
National Defense Medical College
2017-2019
Shimadzu (Japan)
2019
Introduction:Temcell is a mesenchymal stem cell (MSC) product approved for steroid-refractory acute graftversus-host disease (SR-aGVHD) in Japan.However, reports regarding Temcell's efficacy pediatric patients have been scarce, and the appropriate use of MSC therapy against SR-aGVHD also remains to be determined.Patients Methods: We retrospectively assessed cohort treated with Temcell following allogeneic hematopoietic transplantation.MSCs were infused intravenously at dose 2 × 10 6 cells/kg...
The aim of this study was to examine risk factors respiratory complications at the diagnosis and establish an algorithm clinical management in children adolescents with mediastinal tumors.We retrospectively collected information all who presented tumors Saitama Children's Medical Center from 1999 2019, including age, sex, pathological diagnosis, eight major symptoms (cough, dyspnea, hypoxia, orthopnea, chest pain, wheeze, superior vena cava syndrome, stridor), computed tomography (CT)...
Perioperative management of severe congenital protein C deficiency remains unestablished. This is often treated with anticoagulants, such as warfarin. Although anticoagulants need to be perioperatively discontinued, there are few methods for the patients. We adopted a method administering prothrombin complex concentrates (PCC), which includes intermittent administration inactive (PPSB-HT), and examined its outcome perioperative approach deficiency. Three patients underwent our six times....
This study aimed to investigate the clinical outcomes of hematopoietic stem cell transplantation (HSCT) with total body irradiation-based myeloablative conditioning (TBI-MAC) in pediatric patients acute lymphoblastic leukemia (ALL). We retrospectively examined ALL who underwent HSCT TBI-MAC from January 2000 August 2016 at our institute. enrolled 67 a median follow-up period 8 years. The 5-year event-free survival (EFS) and overall (OS) were 51.2% 59.6%, respectively. At first complete...
2019年にdefibrotide(DF)が肝類洞閉塞症候群(sinusoidal obstruction syndrome,SOS)に対する治療薬として本邦で承認されたが,小児の報告は少ない。今回,造血細胞移植を行った際にSOSを発症し,当院でDFを投与した症例の解析を後方視的に行った。症例は4例で疾患の内訳は骨髄異形成症候群(X-linked inhibitor of apoptosis protein,XIAP)欠損症,神経芽腫,急性リンパ性白血病各1例であった。発症直後に原病悪化のため死亡した白血病の1例を除き,3例ともにDF開始後に総ビリルビン値の低下を認めた。1例は多臓器不全のため死亡したが,2例は回復した。DFに関連する明らかな有害事象を認めず,投与早期の総ビリルビン値の低下が治療反応性の予測因子となる傾向があった。小児SOS症例に対するDFの使用経験に関する報告の更なる蓄積が望まれる。
Background. Therapy for relapsed or refractory (r/r) T-cell acute lymphoblastic leukemia (T-ALL) and lymphoma (T-LBL) in children is challenging, new treatment methods are needed. Previous studies have shown a promising response to the addition of nelarabine chemotherapy r/r T-ALL T-LBL. Methods. We retrospectively analyzed therapy combination with etoposide, cyclophosphamide, intrathecal eight pediatric patients The regimen consisted five consecutive days each (650mg/m /dose) etoposide...
Various treatments have been used to treat chronic immune thrombocytopenic purpura in children; however, none of it has established as the standard care. The administration thrombopoietin receptor agonists (TPO-RAs) approved a new treatment option Japan. In this case series, TPO-RAs were administered 16 patients (eltrombopag, n=9; romiplostim, n=7). Excluding data two who underwent splenectomy immediately after starting with these medicines, platelet counts increased ≥50,000/µl seven...